Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 15:382:578170.
doi: 10.1016/j.jneuroim.2023.578170. Epub 2023 Aug 7.

Clinical relevance of thymic and bone marrow outputs in multiple sclerosis patients treated with alemtuzumab

Alessandra Sottini  1 , Virginia Quaresima  2 , Mosè Barbaro  3 , Lucia Moiola  4 , Massimo Filippi  5 , Maria Malentacchi  6 , Marco Capobianco  6 , Marco Puthenparampil  7 , Paolo Gallo  7 , Eleonora Cocco  8 , Jessica Frau  9 , Mauro Zaffaroni  10 , Clara Guaschino  10 , Chiara Stampatori  11 , Chiara Mancinelli  12 , Laura Brambilla  13 , Valentina Torri Clerici  13 , Marika Vianello  14 , Francesca Vitetta  15 , Diana Ferraro  15 , Pamela Rosettani  16 , Maura Chiara Danni  16 , Marta Conti  17 , Maria Grimoldi  17 , Ruggero Capra  11 , Luisa Imberti  18
Affiliations
Free article

Clinical relevance of thymic and bone marrow outputs in multiple sclerosis patients treated with alemtuzumab

Alessandra Sottini et al. J Neuroimmunol. .
Free article

Abstract

Thymic and bone marrow outputs were evaluated in 13 sequential samples of 68 multiple sclerosis patients who initiated alemtuzumab and were clinically followed for 48 months. Three months after alemtuzumab infusions, the levels of new T lymphocytes were significantly reduced, but progressively increased reaching the highest values at 36 months, indicating the remarkable capacity of thymic function recovery. Newly produced B cells exceeded baseline levels as early as 3 months after alemtuzumab initiation. Heterogeneous patterns of new T- and B-cell recovery were identified, but without associations with age, sex, previous therapies, development of secondary autoimmunity or infections, and disease re-emergence. Trial registration version 2.0-27/01/2016.

Keywords: Alemtuzumab; K-deleting recombination excision circles (KRECs); Multiple sclerosis; T-cell receptor excision circles (TRECs).

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare no conflicts of interest with the manuscript. The funding source had no influence on the study design, collection, analysis, and data interpretation. The funding source was not involved in the decision to publish.

Publication types

LinkOut - more resources